secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-02-07T23:59:59+00:00
Accession:  0001437749-25-003070
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton awarded patent for ET-600 desmopressin oral solution expiring 2044; NDA filing expected Q2 2025
--------------------------------------------------------------------------------

- USPTO granted U.S. Patent No. 12,214,010 covering ET-600's proprietary desmopressin oral solution formulation.
- Patent expires in 2044 and is expected to be listed in FDA Orange Book upon product approval.
- ET-600 treats diabetes insipidus; no FDA-approved oral liquid currently available for pediatric patients.
- Pivotal bioequivalence study ongoing; results expected at end of February 2025.
- If positive, NDA filing with FDA anticipated by Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925003070/0001437749-25-003070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925003070/eton20250203_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-003070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer